Business
Cocrystal Pharma, Inc.: To discover and design these direct-acting antiviral drug candidates, we use a proprietary platform comprising computational chemistry, medicinal chemistry, X-ray crystallography and our extensive know-how.
Net income increased 49.5% to ($8.8M), while Operating cash flow increased 50.3% to ($8.2M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($8.8M)Watch
- Cash generation — Free cash flow ($8.2M)Note
- Accounting — Distress score not computed · no manipulation flag · earnings quality not computedNote
- Insiders — 8 buys; 0 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Leadership changes
From Cocrystal Pharma, Inc.'s own filings, the day they're filed.
- James Sapirstein · Chief Executive Officer · appointmenteff. 2026-06-03
- Anthony Japour · directors · departureeff. 2026-03-10
- Forfeiture All · departure
Latest filings
- 8-K · Company announcement2026-08-18
- 8-K · Company announcement2026-08-17
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-03
- 8-K · Company announcement2026-07-17
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cocrystal Pharma, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.